Summit Therapeutics recently released its 10-Q report. Summit is a biopharmaceutical company focused on developing and commercializing oncology therapies, with ivonescimab as its lead candidate. The company says ivonescimab is a bispecific antibody designed to combine PD-1 blockade with anti-angiogenesis activity, and it is being studied in non-small cell lung cancer and colorectal cancer.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Summit said its discussion should be read together with its unaudited condensed consolidated financial statements and the audited year-end 2025 statements in its annual report. It also repeated that much of the section contains forward-looking statements, including language around plans, strategy, and expected outcomes.
Company overview
Summit said its pipeline is centered on oncology and is intended to address serious unmet medical needs. Its lead program, ivonescimab, is described as a potential first-in-class bispecific antibody that combines PD-1 blockade with anti-VEGF activity in a single molecule.
The company disclosed that it licensed rights to develop and commercialize ivonescimab from Akeso in December 2022, with the transaction closing in January 2023. Those rights initially covered the United States, Canada, Europe and Japan, and were expanded in June 2024 to include Latin America, the Middle East and Africa.
Clinical development program
Summit said it is running Phase III trials of ivonescimab in four settings: HARMONi: ivonescimab plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after third-generation EGFR TKI treatment HARMONi-3: ivonescimab plus chemotherapy in first-line metastatic NSCLC HARMONi-7: ivonescimab monotherapy in first-line metastatic NSCLC with high PD-L1 expression HARMONi-GI3: ivonescimab plus chemotherapy in first-line unresectable metastatic CRC
Summit said it completed enrollment in HARMONi in October 2024. In May 2025, it reported topline Phase III results showing a progression-free survival hazard ratio of 0.52 versus placebo plus chemotherapy, with median PFS of 6.8 months versus 4.4 months. It said the OS analysis showed a hazard ratio of 0.79 and did not reach statistical significance.
In September 2025, Summit said an additional OS analysis of Western patients with longer follow-up produced a hazard ratio of 0.78 and a nominal p-value of 0.0332. In that analysis, median OS in Western patients was 17.0 months with ivonescimab versus 14.0 months with placebo; in North American patients, median OS had not yet been reached in the ivonescimab arm versus 14.0 months in the placebo arm.
Summit said it submitted a BLA in the fourth quarter of 2025 for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy. The FDA accepted the filing in January 2026 and set a PDUFA date of November 14, 2026. The agency said a statistically significant OS benefit is necessary to support approval in this setting and that the PFS data may not be sufficient on its own.
HARMONi-3 update
Summit said HARMONi-3 is a Phase III, multi-regional trial comparing ivonescimab plus platinum-based doublet chemotherapy with pembrolizumab plus platinum-based doublet chemotherapy. The company amended the protocol in October 2025 to split the statistical analysis by histology, creating separate analyses for squamous and non-squamous NSCLC.
Summit said it plans to enroll about 600 patients in the squamous cohort and 1,000 in the non-squamous cohort. Enrollment in the squamous cohort was completed in the first quarter of 2026. At an early interim PFS analysis, the independent monitoring committee recommended continuing the study as planned, with no safety concerns noted.
Enrollment in the non-squamous cohort was expected to finish by the end of the second quarter of 2026, with a PFS analysis expected in the first half of 2027.
Collaboration agreements
Summit said it entered a clinical trial collaboration with Revolution Medicines in June 2025 to test ivonescimab with three RAS(ON) inhibitors. In January 2026, it entered another collaboration with GSK to evaluate ivonescimab with risvutatug rezetecan in multiple solid tumors. Summit said neither collaboration includes upfront payments, milestone payments, or royalties, and no cash changed hands in the three months ended March 31, 2026.
License economics with Akeso
Under the Akeso license, Summit said it paid $474.9 million in cash and issued 10 million shares of common stock in lieu of $25.1 million in cash in the first quarter of 2023. It later paid an additional $15.0 million cash upfront in the third quarter of 2024 to expand the territory.
Summit said it may owe Akeso regulatory milestones, sales milestones, and royalties equal to a low-double-digit percentage of annual ivonescimab revenue in the licensed territory. It also said it must buy certain drug substance and/or drug product for clinical and commercial supply and enter into a supply agreement with Akeso.
Summit said it retains final decision-making authority over commercialization, including strategy, pricing, and reimbursement in the licensed territory. As a result of these announcements, the company's shares have moved -0.85% on the market, and are now trading at a price of $22.08. If you want to know more, read the company's complete 10-Q report here.
